MedImmune - Articles and news items

Inducing protein aggregation by extensional flow makes drugs less effective

Industry news / 9 May 2017 / University of Leeds

Data from a new device demonstrates maximal levels of extensional flow which manufacturers could use for different processes, without damaging proteins…

AstraZeneca’s potential drug for neuromyelitis optica spectrum disorder receives EU orphan designation

Industry news / 30 March 2017 / Niamh Marriott, Junior Editor

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the European Medicines Agency (EMA) has granted orphan designation to inebilizumab (formerly MEDI-551) for the treatment of neuromyelitis optica spectrum disorder (NMOSD).

MedImmune out-licenses inflammatory diseases medicine to Allergan

Industry news / 3 October 2016 / Niamh Louise Marriott, Digital Content Producer

MEDI2070 is an IL-23 monoclonal antibody currently in a Phase IIb trial for Crohn’s disease (a chronic inflammatory disease of the intestines) and is…

FSA grants Fast Track designation for MEDI8852

Industry news / 7 March 2016 / Victoria White

MedImmune has received Fast Track designation from the FDA for MEDI8852 for the treatment of patients hospitalised with Type A strain influenza…

Tremelimumab mesothelioma trial fails to meet primary endpoint

Industry news / 29 February 2016 / Victoria White

DETERMINE, the Phase IIb clinical trial of tremelimumab monotherapy in second or third-line treatment of unresectable malignant mesothelioma, did not meet its primary endpoint of overall survival…

Trial of IMCgp100, durvalumab and tremelimumab in melanoma starts

Industry news / 20 January 2016 / Victoria White

Immunocore has announced the start of the Phase Ib/II combination trial evaluating IMCgp100 with durvalumab and tremelimumab for the treatment of metastatic cutaneous melanoma…

Medimmune to develop DNA-based immunotherapies for cancer and infectious diseases

Medimmune and Inovio Pharmaceuticals agree to DNA-based immunotherapy collaboration

Industry news / 11 August 2015 / Katie Sadler, Digital Content Producer, European Pharmaceutical Review

AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a license agreement and collaboration with Inovio Pharmaceuticals, a biotechnology company developing DNA-based immunotherapies for cancer and infectious diseases.

Innate Pharma and Astrazeneca announce co-development and commercialisation collaboration for IPH2201

Industry news / 24 April 2015 / Victoria White

Innate Pharma has signed a co-development and commercialisation agreement with AstraZeneca to accelerate and broaden the development of IPH2201…


MedImmune and Immunocore collaborate to conduct immuno-oncology combination trials in metastatic melanoma

Industry news / 17 April 2015 / Victoria White

MedImmune has entered into a collaboration with Immunocore to conduct immuno-oncology combination trials in metastic melanoma…

MEDI8897 receives FDA Fast Track designation for the prevention of respiratory disease caused by RSV in infants

Industry news / 9 April 2015 / Victoria White

MedImmune has announced that it has received fast track designation from the U.S. Food and Drug Administration (FDA) for the development of MEDI8897…


Advaxis submits investigational new drug application for Phase 1/2 study of ADXS-HPV and Medimmune’s medi4736 for the treatment of HPV-associated cervical and head & neck cancer

Industry news / 14 November 2014 / MedImmune and Advaxis

Dose confirmation safety study of ADXS-HPV and MEDI4736 combination therapy to initiate in early 2015…


MedImmune strengthens immuno-oncology capabilities with acquisition of Definiens

Industry news / 7 November 2014 / AstraZeneca

AstraZeneca announced that MedImmune, its global biologics research and development arm, has entered into an agreement to acquire Definiens, a privately-held company that has pioneered a world-leading imaging and data analysis technology, known as Tissue Phenomics™, which dramatically improves the identification of biomarkers in tumour tissue…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...